Stereotactic body radiation therapy for inoperable early stage lung cancer

Robert Timmerman, Rebecca Paulus, James Galvin, Jeffrey Michalski, William Straube, Jeffrey Bradley, Achilles Fakiris, Andrea Bezjak, Gregory Videtic, David Johnstone, Jack Fowler, Elizabeth Gore, Hak Choy

Research output: Contribution to journalArticle

1440 Citations (Scopus)

Abstract

Context: Patients with early stage but medically inoperable lung cancer have a poor rate of primary tumor control (30%-40%) and a high rate of mortality (3-year survival, 20%-35%) with current management. Objective: To evaluate the toxicity and efficacy of stereotactic body radiation therapy in a high-risk population of patients with early stage but medically inoperable lung cancer. Design, Setting, and Patients: Phase 2 North American multicenter study of patients aged 18 years or older with biopsy-proven peripheral T1-T2N0M0 non-small cell tumors (measuring <5 cm in diameter) and medical conditions precluding surgical treatment. The prescription dose was 18 Gy per fraction x 3 fractions (54 Gy total) with entire treatment lasting between 11/2 and 2 weeks. The study opened May 26, 2004, and closed October 13, 2006; data were analyzed through August 31, 2009. Main Outcome Measures: The primary end point was 2-year actuarial primary tumor control; secondary end points were disease-free survival (ie, primary tumor, involved lobe, regional, and disseminated recurrence), treatment-related toxicity, and overall survival. Results: A total of 59 patients accrued, of which 55 were evaluable (44 patients with T1 tumors and 11 patients with T2 tumors) with a median follow-up of 34.4 months (range, 4.8-49.9 months). Only 1 patient had a primary tumor failure; the estimated 3-year primary tumor control rate was 97.6% (95% confidence interval [CI], 84.3%-99.7%). Three patients had recurrence within the involved lobe; the 3-year primary tumor and involved lobe (local) control rate was 90.6% (95% CI, 76.0%-96.5%). Two patients experienced regional failure; the local-regional control rate was 87.2% (95% CI, 71.0%-94.7%). Eleven patients experienced disseminated recurrence; the 3-year rate of disseminated failure was 22.1% (95% CI, 12.3%-37.8%). The rates for diseasefree survival and overall survival at 3 years were 48.3% (95% CI, 34.4%-60.8%) and 55.8% (95% CI, 41.6%-67.9%), respectively. The median overall survival was 48.1 months (95% CI, 29.6 months to not reached). Protocol-specified treatment-related grade 3 adverse events were reported in 7 patients (12.7%; 95% CI, 9.6%-15.8%); grade 4 adverse events were reported in 2 patients (3.6%; 95% CI, 2.7%-4.5%). No grade 5 adverse events were reported. Conclusion Patients with inoperable non-small cell lung cancer who received stereotactic body radiation therapy had a survival rate of 55.8% at 3 years, high rates of local tumor control, and moderate treatment-related morbidity.

Original languageEnglish (US)
Pages (from-to)1070-1076
Number of pages7
JournalJAMA - Journal of the American Medical Association
Volume303
Issue number11
DOIs
StatePublished - Mar 17 2010

Fingerprint

Lung Neoplasms
Radiotherapy
Confidence Intervals
Neoplasms
Survival
Recurrence
Survival Rate
Therapeutics
Clinical Protocols
Non-Small Cell Lung Carcinoma
Multicenter Studies
Disease-Free Survival
Prescriptions
Outcome Assessment (Health Care)
Morbidity
Biopsy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Stereotactic body radiation therapy for inoperable early stage lung cancer. / Timmerman, Robert; Paulus, Rebecca; Galvin, James; Michalski, Jeffrey; Straube, William; Bradley, Jeffrey; Fakiris, Achilles; Bezjak, Andrea; Videtic, Gregory; Johnstone, David; Fowler, Jack; Gore, Elizabeth; Choy, Hak.

In: JAMA - Journal of the American Medical Association, Vol. 303, No. 11, 17.03.2010, p. 1070-1076.

Research output: Contribution to journalArticle

Timmerman, R, Paulus, R, Galvin, J, Michalski, J, Straube, W, Bradley, J, Fakiris, A, Bezjak, A, Videtic, G, Johnstone, D, Fowler, J, Gore, E & Choy, H 2010, 'Stereotactic body radiation therapy for inoperable early stage lung cancer', JAMA - Journal of the American Medical Association, vol. 303, no. 11, pp. 1070-1076. https://doi.org/10.1001/jama.2010.261
Timmerman, Robert ; Paulus, Rebecca ; Galvin, James ; Michalski, Jeffrey ; Straube, William ; Bradley, Jeffrey ; Fakiris, Achilles ; Bezjak, Andrea ; Videtic, Gregory ; Johnstone, David ; Fowler, Jack ; Gore, Elizabeth ; Choy, Hak. / Stereotactic body radiation therapy for inoperable early stage lung cancer. In: JAMA - Journal of the American Medical Association. 2010 ; Vol. 303, No. 11. pp. 1070-1076.
@article{fe1d05eb6185459ea06c2338f1caaa89,
title = "Stereotactic body radiation therapy for inoperable early stage lung cancer",
abstract = "Context: Patients with early stage but medically inoperable lung cancer have a poor rate of primary tumor control (30{\%}-40{\%}) and a high rate of mortality (3-year survival, 20{\%}-35{\%}) with current management. Objective: To evaluate the toxicity and efficacy of stereotactic body radiation therapy in a high-risk population of patients with early stage but medically inoperable lung cancer. Design, Setting, and Patients: Phase 2 North American multicenter study of patients aged 18 years or older with biopsy-proven peripheral T1-T2N0M0 non-small cell tumors (measuring <5 cm in diameter) and medical conditions precluding surgical treatment. The prescription dose was 18 Gy per fraction x 3 fractions (54 Gy total) with entire treatment lasting between 11/2 and 2 weeks. The study opened May 26, 2004, and closed October 13, 2006; data were analyzed through August 31, 2009. Main Outcome Measures: The primary end point was 2-year actuarial primary tumor control; secondary end points were disease-free survival (ie, primary tumor, involved lobe, regional, and disseminated recurrence), treatment-related toxicity, and overall survival. Results: A total of 59 patients accrued, of which 55 were evaluable (44 patients with T1 tumors and 11 patients with T2 tumors) with a median follow-up of 34.4 months (range, 4.8-49.9 months). Only 1 patient had a primary tumor failure; the estimated 3-year primary tumor control rate was 97.6{\%} (95{\%} confidence interval [CI], 84.3{\%}-99.7{\%}). Three patients had recurrence within the involved lobe; the 3-year primary tumor and involved lobe (local) control rate was 90.6{\%} (95{\%} CI, 76.0{\%}-96.5{\%}). Two patients experienced regional failure; the local-regional control rate was 87.2{\%} (95{\%} CI, 71.0{\%}-94.7{\%}). Eleven patients experienced disseminated recurrence; the 3-year rate of disseminated failure was 22.1{\%} (95{\%} CI, 12.3{\%}-37.8{\%}). The rates for diseasefree survival and overall survival at 3 years were 48.3{\%} (95{\%} CI, 34.4{\%}-60.8{\%}) and 55.8{\%} (95{\%} CI, 41.6{\%}-67.9{\%}), respectively. The median overall survival was 48.1 months (95{\%} CI, 29.6 months to not reached). Protocol-specified treatment-related grade 3 adverse events were reported in 7 patients (12.7{\%}; 95{\%} CI, 9.6{\%}-15.8{\%}); grade 4 adverse events were reported in 2 patients (3.6{\%}; 95{\%} CI, 2.7{\%}-4.5{\%}). No grade 5 adverse events were reported. Conclusion Patients with inoperable non-small cell lung cancer who received stereotactic body radiation therapy had a survival rate of 55.8{\%} at 3 years, high rates of local tumor control, and moderate treatment-related morbidity.",
author = "Robert Timmerman and Rebecca Paulus and James Galvin and Jeffrey Michalski and William Straube and Jeffrey Bradley and Achilles Fakiris and Andrea Bezjak and Gregory Videtic and David Johnstone and Jack Fowler and Elizabeth Gore and Hak Choy",
year = "2010",
month = "3",
day = "17",
doi = "10.1001/jama.2010.261",
language = "English (US)",
volume = "303",
pages = "1070--1076",
journal = "JAMA - Journal of the American Medical Association",
issn = "0098-7484",
publisher = "American Medical Association",
number = "11",

}

TY - JOUR

T1 - Stereotactic body radiation therapy for inoperable early stage lung cancer

AU - Timmerman, Robert

AU - Paulus, Rebecca

AU - Galvin, James

AU - Michalski, Jeffrey

AU - Straube, William

AU - Bradley, Jeffrey

AU - Fakiris, Achilles

AU - Bezjak, Andrea

AU - Videtic, Gregory

AU - Johnstone, David

AU - Fowler, Jack

AU - Gore, Elizabeth

AU - Choy, Hak

PY - 2010/3/17

Y1 - 2010/3/17

N2 - Context: Patients with early stage but medically inoperable lung cancer have a poor rate of primary tumor control (30%-40%) and a high rate of mortality (3-year survival, 20%-35%) with current management. Objective: To evaluate the toxicity and efficacy of stereotactic body radiation therapy in a high-risk population of patients with early stage but medically inoperable lung cancer. Design, Setting, and Patients: Phase 2 North American multicenter study of patients aged 18 years or older with biopsy-proven peripheral T1-T2N0M0 non-small cell tumors (measuring <5 cm in diameter) and medical conditions precluding surgical treatment. The prescription dose was 18 Gy per fraction x 3 fractions (54 Gy total) with entire treatment lasting between 11/2 and 2 weeks. The study opened May 26, 2004, and closed October 13, 2006; data were analyzed through August 31, 2009. Main Outcome Measures: The primary end point was 2-year actuarial primary tumor control; secondary end points were disease-free survival (ie, primary tumor, involved lobe, regional, and disseminated recurrence), treatment-related toxicity, and overall survival. Results: A total of 59 patients accrued, of which 55 were evaluable (44 patients with T1 tumors and 11 patients with T2 tumors) with a median follow-up of 34.4 months (range, 4.8-49.9 months). Only 1 patient had a primary tumor failure; the estimated 3-year primary tumor control rate was 97.6% (95% confidence interval [CI], 84.3%-99.7%). Three patients had recurrence within the involved lobe; the 3-year primary tumor and involved lobe (local) control rate was 90.6% (95% CI, 76.0%-96.5%). Two patients experienced regional failure; the local-regional control rate was 87.2% (95% CI, 71.0%-94.7%). Eleven patients experienced disseminated recurrence; the 3-year rate of disseminated failure was 22.1% (95% CI, 12.3%-37.8%). The rates for diseasefree survival and overall survival at 3 years were 48.3% (95% CI, 34.4%-60.8%) and 55.8% (95% CI, 41.6%-67.9%), respectively. The median overall survival was 48.1 months (95% CI, 29.6 months to not reached). Protocol-specified treatment-related grade 3 adverse events were reported in 7 patients (12.7%; 95% CI, 9.6%-15.8%); grade 4 adverse events were reported in 2 patients (3.6%; 95% CI, 2.7%-4.5%). No grade 5 adverse events were reported. Conclusion Patients with inoperable non-small cell lung cancer who received stereotactic body radiation therapy had a survival rate of 55.8% at 3 years, high rates of local tumor control, and moderate treatment-related morbidity.

AB - Context: Patients with early stage but medically inoperable lung cancer have a poor rate of primary tumor control (30%-40%) and a high rate of mortality (3-year survival, 20%-35%) with current management. Objective: To evaluate the toxicity and efficacy of stereotactic body radiation therapy in a high-risk population of patients with early stage but medically inoperable lung cancer. Design, Setting, and Patients: Phase 2 North American multicenter study of patients aged 18 years or older with biopsy-proven peripheral T1-T2N0M0 non-small cell tumors (measuring <5 cm in diameter) and medical conditions precluding surgical treatment. The prescription dose was 18 Gy per fraction x 3 fractions (54 Gy total) with entire treatment lasting between 11/2 and 2 weeks. The study opened May 26, 2004, and closed October 13, 2006; data were analyzed through August 31, 2009. Main Outcome Measures: The primary end point was 2-year actuarial primary tumor control; secondary end points were disease-free survival (ie, primary tumor, involved lobe, regional, and disseminated recurrence), treatment-related toxicity, and overall survival. Results: A total of 59 patients accrued, of which 55 were evaluable (44 patients with T1 tumors and 11 patients with T2 tumors) with a median follow-up of 34.4 months (range, 4.8-49.9 months). Only 1 patient had a primary tumor failure; the estimated 3-year primary tumor control rate was 97.6% (95% confidence interval [CI], 84.3%-99.7%). Three patients had recurrence within the involved lobe; the 3-year primary tumor and involved lobe (local) control rate was 90.6% (95% CI, 76.0%-96.5%). Two patients experienced regional failure; the local-regional control rate was 87.2% (95% CI, 71.0%-94.7%). Eleven patients experienced disseminated recurrence; the 3-year rate of disseminated failure was 22.1% (95% CI, 12.3%-37.8%). The rates for diseasefree survival and overall survival at 3 years were 48.3% (95% CI, 34.4%-60.8%) and 55.8% (95% CI, 41.6%-67.9%), respectively. The median overall survival was 48.1 months (95% CI, 29.6 months to not reached). Protocol-specified treatment-related grade 3 adverse events were reported in 7 patients (12.7%; 95% CI, 9.6%-15.8%); grade 4 adverse events were reported in 2 patients (3.6%; 95% CI, 2.7%-4.5%). No grade 5 adverse events were reported. Conclusion Patients with inoperable non-small cell lung cancer who received stereotactic body radiation therapy had a survival rate of 55.8% at 3 years, high rates of local tumor control, and moderate treatment-related morbidity.

UR - http://www.scopus.com/inward/record.url?scp=77949520655&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949520655&partnerID=8YFLogxK

U2 - 10.1001/jama.2010.261

DO - 10.1001/jama.2010.261

M3 - Article

VL - 303

SP - 1070

EP - 1076

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0098-7484

IS - 11

ER -